
    
      During the whole study, patients meet a physician on a regular basis. Safety is assessed by
      adverse event spontaneous reporting、physical examination、recording of vital signs、laboratory
      tests and electrocardiogram at baseline and 16 week . Blood samples are collected for
      centralized measure of HbA1C and fasting serum insulin(FSI)、PSI1/2、PSI2 after an overnight
      fast in all patients,Body weight, supine and standing blood pressures and heart rate are
      measured at each clinical visit. Adverse events are rated as mild, moderate or severe by the
      investigators and assessed for any causal relationship to the study drugs. Patients are
      entitled to interrupt the treatment at any time during the study, and investigators can
      withdraw patients, in particular if they are inadequately controlled.
    
  